These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 30204343)

  • 21. Steroid-induced ocular hypertension with loteprednol etabonate 0.2%--a case report.
    Lu E; Fujimoto LT; Vejabul PA; Jew RL
    Optometry; 2011 Jul; 82(7):413-20. PubMed ID: 21543264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.
    Easthope SE; Perry CM
    Drugs Aging; 2002; 19(3):231-48. PubMed ID: 12027782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intraocular pressure changes in the contralateral eye after topical treatment: does an "ophthalmotonic consensual reaction" exist?
    Newman H; Kurtz S; David R
    Isr Med Assoc J; 2010 Sep; 12(9):568-71. PubMed ID: 21287803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monocular trial of intraocular pressure-lowering medication: a prospective study.
    King AJ; Uppal S; Rotchford AP; Lakshumanan A; Abedin A; Henry E
    Ophthalmology; 2011 Nov; 118(11):2190-5. PubMed ID: 21724262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma.
    Christiansen GA; Nau CB; McLaren JW; Johnson DH
    Ophthalmology; 2004 Sep; 111(9):1658-62. PubMed ID: 15350319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study.
    Weinreb RN; Scassellati Sforzolini B; Vittitow J; Liebmann J
    Ophthalmology; 2016 May; 123(5):965-73. PubMed ID: 26875002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short-term effect of latanoprost on ocular circulation in ocular hypertension.
    Akarsu C; Bilgili YK; Taner P; Unal B; Ergin A
    Clin Exp Ophthalmol; 2004 Aug; 32(4):373-7. PubMed ID: 15281970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bimatoprost versus travoprost in an Egyptian population: a hospital-based prospective, randomized study.
    Macky TA
    J Ocul Pharmacol Ther; 2010 Dec; 26(6):605-10. PubMed ID: 21034177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension.
    Balfour JA; Wilde MI
    Drugs Aging; 1997 May; 10(5):384-403. PubMed ID: 9143858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of ocular hypotensive medication types with dynamic contour tonometry and Goldmann applanation tonometry measurements in a glaucoma and ocular hypertensive population.
    Tzamalis A; Kynigopoulos M; Chalvatzis N; Dimitrakos S; Schlote T
    J Ocul Pharmacol Ther; 2013 Feb; 29(1):41-7. PubMed ID: 23066787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure.
    Bacharach J; Dubiner HB; Levy B; Kopczynski CC; Novack GD;
    Ophthalmology; 2015 Feb; 122(2):302-7. PubMed ID: 25270273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Ocular hypotensive effect of 1% carteolol long-acting eye drops--a double-masked, randomized phase III study in ocular hypertension or primary open-angle glaucoma patients comparing long-acting carteolol eye drops vs. current product].
    Yamamoto T;
    Nippon Ganka Gakkai Zasshi; 2007 Jun; 111(6):463-72. PubMed ID: 17601060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduction of enhanced rabbit intraocular pressure by instillation of pyroglutamic acid eye drops.
    Ito Y; Nagai N; Okamoto N; Shimomura Y; Nakanishi K; Tanaka R
    Biol Pharm Bull; 2013; 36(6):1017-23. PubMed ID: 23727922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of bimatoprost on intraocular pressure after cataract surgery.
    Unal M; Yücel I
    Can J Ophthalmol; 2008 Dec; 43(6):712-6. PubMed ID: 19020639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Bottoli A; Fogagnolo P
    Ophthalmology; 2006 Feb; 113(2):239-46. PubMed ID: 16458092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A water-soluble carbon monoxide-releasing molecule (CORM-3) lowers intraocular pressure in rabbits.
    Stagni E; Privitera MG; Bucolo C; Leggio GM; Motterlini R; Drago F
    Br J Ophthalmol; 2009 Feb; 93(2):254-7. PubMed ID: 18977789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcome of raised intraocular pressure in uveitic eyes with and without a corticosteroid-induced hypertensive response.
    Sallam A; Sheth HG; Habot-Wilner Z; Lightman S
    Am J Ophthalmol; 2009 Aug; 148(2):207-213.e1. PubMed ID: 19403113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
    Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K
    J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution.
    Barnebey HS; Orengo-Nania S; Flowers BE; Samples J; Mallick S; Landry TA; Bergamini MV
    Am J Ophthalmol; 2005 Jul; 140(1):1-7. PubMed ID: 15990081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of latanoprost, bimatoprost, and travoprost on intraocular pressure after cataract surgery.
    Arici MK; Erdogan H; Toker I; Vural A; Topalkara A
    J Ocul Pharmacol Ther; 2006 Feb; 22(1):34-40. PubMed ID: 16503773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.